Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Okt 2011 - :1432-0851 [PMID:22021066] [Chu CS] [Boyer J] [Schullery DS] [Gimotty PA] [Gamerman V] [Bender J] [Levine BL] [Coukos G] [Rubin SC] [Morgan MA] [Vonderheide RH] [June CH]
Dendritic cell vaccination against ovarian cancer - tipping the Treg/T(H)17 balance to therapeutic advantage? Mrz 2011 - Expert Opin Biol Ther; 11(4):1744-7682 [PMID:21271951] [Cannon MJ] [Goyne H] [Stone PJ] [Chiriva-Internati M]
Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study. Feb 2010 - Int J Hyperthermia; 26(2):1464-5157 [PMID:20146566] [Fotopoulou C] [Hee Cho C] [Kraetschell R] [Gellermann J] [Wust P] [Lichtenegger W] [Sehouli J]
Ovarian cancer immunotherapy: opportunities, progresses and challenges. Feb 2010 - ; 3(1):1756-8722 [PMID:20146807] [Liu B] [Nash J] [Runowicz C] [Swede H] [Stevens R] [Li Z]
Cellular immunotherapy for ovarian cancer. Mai 2009 - Expert Opin Biol Ther; 9(6):1744-7682 [PMID:19456205] [Cannon MJ] [O'Brien TJ]
Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer - a phase II study. Jan 2009 - Gynecol. Oncol.; 112(2):1095-6859 [PMID:19059635] [Atmaca A] [Al-Batran SE] [Neumann A] [Kolassa Y] [Jäger D] [Knuth A] [Jäger E]
Ovarian cancer detection and treatment: current situation and future prospects. Nov 2008 - Anticancer Res.; 28(5B):0250-7005 [PMID:19031970] [Argento M] [Hoffman P] [Gauchez AS]
Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Apr 2007 - Lancet Oncol.; 8(5):1470-2045 [PMID:17466904] [Hernando JJ] [Park TW] [Fischer HP] [Zivanovic O] [Braun M] [Pölcher M] [Grünn U] [Leutner C] [Pötzsch B] [Kuhn W]
Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. Feb 2006 - Cancer Gene Ther.; 13(2):0929-1903 [PMID:16138121] [Courrèges MC] [Benencia F] [Conejo-García JR] [Zhang L] [Coukos G]
Current approaches in ovarian cancer vaccines. Feb 2005 - Minerva Ginecol; 56(6):0026-4784 [PMID:15729204] [Reinartz S] [Wagner U]
[Immunotherapy--perspectives in therapy of ovarian carcinomas] Dez 2004 - Ceska Gynekol; 69(5):1210-7832 [PMID:15587893] [Zapletalová K] [Tobiasová Z] [Spísek R] [Rob L] [Bartůnková J]
Immunological treatment of ovarian cancer. Mai 2004 - Curr. Opin. Obstet. Gynecol.; 16(1):1040-872X [PMID:15128013] [Cannon MJ] [Santin AD] [O'Brien TJ]
Dendritic cell-based vaccines in breast and gynaecologic cancer. Jan 2004 - Anticancer Res.; 23(5b):0250-7005 [PMID:14666641] [Hernando JJ] [Park TW] [Kuhn WC]
TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Apr 2003 - Clin. Cancer Res.; 9(4):1078-0432 [PMID:12684428] [Schlienger K] [Chu CS] [Woo EY] [Rivers PM] [Toll AJ] [Hudson B] [Maus MV] [Riley JL] [Choi Y] [Coukos G] [Kaiser LR] [Rubin SC] [Levine BL] [Carroll RG] [June CH]
Dendritic cells in vaccination therapies of malignant diseases. Sep 2002 - Transfus. Apher. Sci.; 27(2):1473-0502 [PMID:12350054] [Brossart P] [Brossart M D P]
